Swedish biopharmaceutical company Aprea Therapeutics reported on Tuesday the receipt of the US Food and Drug Administration (FDA) Fast Track designation for expediting the development, review and potential approval of APR-246 for the treatment of patients with MDS having a TP53 mutation.
Myelodysplastic syndromes (MDS) represents a spectrum of hematopoietic stem cell malignancies in which bone marrow fails to produce sufficient healthy blood cells. Approximately 30-40% of MDS patients progress to acute myeloid leukemia (AML) and mutation of the p53 tumour suppressor protein is thought to contribute to disease progression. Mutations in p53 are found in approximately 20% of MDS and AML patients and are associated with poor overall prognosis.
Concurrently, the company has received US FDA Orphan Drug Designation for APR-246 for MDS. The ODD provides seven-year period of market exclusivity in the US after product approval, US FDA assistance in clinical trial design, tax credits related to clinical trial expenses as well as exemption from US FDA user fees.
The company added that the p53 tumour suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumours. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.
APR-246 has demonstrated pre-clinical anti-tumour activity in a wide variety of solid and hematological (blood) tumours, including MDS, AML and ovarian cancer. A Phase I/II clinical programme with APR-246 demonstrated a favorable safety profile, biological activity and clinical responses in hematological malignancies and solid tumours with mutations in the TP53 gene, concluded the company.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia